



Enjuvia[®] (synthetic conjugated estrogens, B) – Product Discontinuation

- Recently, the [FDA announced](#) the discontinuation of [Enjuvia \(synthetic conjugated estrogens, B\)](#) due to business reasons.
 - The discontinuation is not due to product quality, safety, or efficacy concerns.
 - Per Teva, the 0.3 mg and 0.45 mg tablets were discontinued in June 2016 and the 0.625 mg, 0.9 mg and 1.25 mg tablets were discontinued in July 2016.
- Enjuvia is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause, and for the treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, due to menopause.
- Other currently available oral estrogen products that share similar indications as Enjuvia include [Estrace[®] \(estradiol\)](#), [estropipate](#), [Menest[®] \(esterified estrogens\)](#), and [Premarin[®] \(conjugated estrogens\)](#). Refer to individual drug labels for specific indication information.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.